Biogen Inc. (BIIB)

225.76
2.55 1.14
NASDAQ : Health Technology
Prev Close 223.21
Open 222.50
Day Low/High 221.84 / 226.38
52 Wk Low/High 215.78 / 344.00
Volume 2.55M
Avg Volume 1.43M
Exchange NASDAQ
Shares Outstanding 184.45M
Market Cap 41.13B
EPS 21.60
P/E Ratio 8.31
Div & Yield N.A. (N.A)

Latest News

No Shortage of Candidates for the Next Portfolio of Losers

No Shortage of Candidates for the Next Portfolio of Losers

Dozens of beaten-up stocks could see tax-loss selling into the end of the year; here's a preview of some that could make up the next Tax Loss Selling Portfolio.

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon Beta-1a) And AVONEX® (interferon Beta-1a), Receive Positive CHMP Opinion For Use During Pregnancy And Breastfeeding

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon Beta-1a) And AVONEX® (interferon Beta-1a), Receive Positive CHMP Opinion For Use During Pregnancy And Breastfeeding

Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during first trimester Data show pregnancy...

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research With New Study Evaluating A Higher Dose Of SPINRAZA® (nusinersen) And Additional Data In A Broad Range Of Patients

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research With New Study Evaluating A Higher Dose Of SPINRAZA® (nusinersen) And Additional Data In A Broad Range Of Patients

DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term data from the SHINE study demonstrate improvements in or...

S&P 500 Buybacks Decline Significantly In Q2 2019; Expenditures Still Remain Higher Than The Pre-2018 Levels

S&P 500 Buybacks Decline Significantly In Q2 2019; Expenditures Still Remain Higher Than The Pre-2018 Levels

- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018.

Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials

Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials

Results of a safety review convinces Biogen to shut down the trials of its experimental Alzheimer's treatment.

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Discontinuation of studies based on Data Safety Monitoring Board recommendation

New Research Demonstrate Biogen's Continued Commitment To Improve Care Of Patients With Multiple Sclerosis Across Treatment Spectrum

New Research Demonstrate Biogen's Continued Commitment To Improve Care Of Patients With Multiple Sclerosis Across Treatment Spectrum

Data highlight benefits of TYSABRI ® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognition An analysis of data from the TYSABRI Observational Program (TOP)...

New Data Presented At ECTRIMS Reinforce Long-term Benefits Of TECFIDERA® (dimethyl Fumarate) Over 10 Years

New Data Presented At ECTRIMS Reinforce Long-term Benefits Of TECFIDERA® (dimethyl Fumarate) Over 10 Years

TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatment Latest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and Alkermes' investigational treatment, diroximel...

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Biogen And Invitae Announce Availability Of Rapid Results In Genetic Testing Program For Spinal Muscular Atrophy (SMA) To Improve Speed Of Diagnosis For Patients

Biogen And Invitae Announce Availability Of Rapid Results In Genetic Testing Program For Spinal Muscular Atrophy (SMA) To Improve Speed Of Diagnosis For Patients

New SMA STAT genetic test reduces time to provide results from 21 to four days to aid in clinical care Early treatment of SMA has been shown to slow disease progression and improve or stabilize loss of motor function SMA Identified program offers genetic...

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate — DUBLIN,...

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Release Your 'Inner Spock' When Investing in Biotech Stocks

Release Your 'Inner Spock' When Investing in Biotech Stocks

Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

The drugmaker reports second-quarter results that beat analysts' forecasts and raises its guidance for the remainder of the year on strong demand for its multiple sclerosis and other disease-fighting medications.

Apple, Coca-Cola, Snap, Facebook, Debt Ceiling - 5 Things You Must Know

Apple, Coca-Cola, Snap, Facebook, Debt Ceiling - 5 Things You Must Know

U.S. stock futures rise ahead of earnings reports from a number of corporate heavyweights and after the White House and congressional negotiators reach a budget deal that will lift the government's debt limit; Coca-Cola, Snap, Visa and Harley-Davidson are among the companies reporting earnings on Tuesday; Apple reportedly is in talks to buy Intel's modem chip business for $1 billion.

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) As A Foundation Of Care In Spinal Muscular Atrophy For A Broad Range Of Patients

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) As A Foundation Of Care In Spinal Muscular Atrophy For A Broad Range Of Patients

- New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

Biogen Could Rally in the Weeks Ahead

Biogen Could Rally in the Weeks Ahead

Buyers have returned in recent months and the stock could be ready to rise.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Getting Nervous

After days of complacency, we see a shift in sentiment and folks are getting the jitters.

TheStreet Quant Rating: C (Hold)